Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 17/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 5/20 | 0.51 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 0.51 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.51 |
| ▸ | PLA2G2F | Q9BZM2 | 3/20 | 0.49 |
| ▸ | PLA2G2D | Q9UNK4 | 3/20 | 0.49 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.49 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.49 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718771 | 0.91 | PLA2G2A (0.53) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL6727355 | 0.89 | PLA2G2A (0.55) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL5212158 | 0.88 | PLA2G2A (0.56) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL7246280 | 0.86 | PLA2G2A (0.53) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL5208128 | 0.86 | PLA2G2A (0.55) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL29862240 | 0.86 | PLA2G2A (0.63) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL817831 | 0.86 | PLA2G2A (0.63) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL6610906 | 0.85 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL5211343 | 0.84 | PLA2G2A (0.55) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B | |
| SCHEMBL5213070 | 0.84 | PLA2G2A (0.53) | PLA2G2APLA2G10PLA2G2EPLA2G5PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204473-A1 | Substituted tricyclics | LIN HO-SHEN (US) | 2004-10-14 | — | — | US | claimed |
| EP-1248769-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001049662-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| US-20040204473-A1 | Substituted tricyclics | LIN HO-SHEN (US) | 2004-10-14 | — | — | US | disclosed |
| US-20030096854-A1 | Substituted tricyclics | ELI LILLY AND COMPANY | 2003-05-22 | — | — | US | disclosed |
| EP-1248769-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001049662-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096854-A1 | Substituted tricyclics | LITAF, PLA2G4A, LTC4S | PLA2G2A 34/4885PLA2G10 78/4885PLA2G2E 25/4885 |
| US-20040204473-A1 | Substituted tricyclics | PLA2G4A, PLAA, LTC4S | PLA2G2A 28/4885PLA2G10 58/4885PLA2G2E 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.